162 Current Drug Safety, 2012, Vol. 7, No. 2 moxifloxacin should not be used in patients with known pro- arrhythmic conditions [33, 34] the overall cardiac safety of moxifloxacin, orally or intravenously, appears to be comparable to that of other commonly used antibiotics. The cardiac safety profile of moxifloxacin provided in this manuscript is in accordance with safety profiles presented by other groups independently from Bayer. ACKNOWLEDGEMENTS The authors are grateful to Paul Tulkens, Université catholique de Louvain, Brussels; Marc Vos, Departement of Medical Physiology, Heart and Lungs Division, UMC Utrecht, The Netherlands; and Nikolaus Schmage, Global Pharmacovigilance, PV Risk Management, Bayer Pharma AG, Berlin, Germany for critically reviewing early drafts of the manuscript. Medical writing services were provided by Highfield Communication Consultancy, funded by Bayer Pharma AG. CONFLICT OF INTEREST Frank Kruesmann, Anna Fritsch, David van Veenhuyzen and Pierre Arvis are employees of Bayer Pharma AG. REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol Clin Exp 2008; 23(Suppl 1): 3-14. Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007; 13(7 Suppl): S178-88. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47: 219-33. Salvi V, Karnad DR, Panicker GK, Kothari S. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 2010; 159: 34-48. Estelle F, Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999; 83: 481-8. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 2002; 1: 121-8. Ketek® 400 mg tablets. Summary of Product Characteristics. Sanofi-Aventis, UK, updated 03/06/2008. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 1996; 37(Suppl A): 161-7. Ball P. Quinolone-induced QT interval prolongation: a not-so- unexpected class effect. J Antimicrob Chemother 2000; 45: 557-9. van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359-78. Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-66. Taubel J, Naseem A, Harada T, et al. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. Br J Clin Pharmacol 2010; 69: 391-400. Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21: 301-19. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Haverkamp et al. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010; 33: 303-14. Chen X, Cass JD, Bradley JA, et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 2005; 146: 792-9. Alexandrou AJ, Duncan RS, Sullivan A, et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 2006; 147: 905-16. Malik M, Garnett CE, Zhang J. Thorough QT studies: questions and quandaries. Drug Saf 2010; 33: 1-14. Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 2009; 49: 674-83. Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-54. Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz P and the MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697-705. Torres A, Garau J, Arvis P, et al.; MOTIV (MOxifloxacin Treatment IV) Study Group. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin Infect Dis 2008; 46: 1499-509. Weiss G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H; AIDA Study Group. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother 2009; 21: 170-80. Faich GA, Morganroth J, Whitehouse AB, et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004; 38: 749-54. Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128: 3398-406. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998; 280: 1774-6. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-7. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8: 690-5. Mangoni AA, Kinirons MT, Swift CG, Jackson SH. Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. Age Ageing 2003; 32: 326-31. EMA/CHMP/PhVWP. Monthly Report. Accessed: http://www.em a.europa.eu/docs/en_GB/document_library/Report/2011/01/WC500 100459.pdf Romero K, Woosley R. Clarification to the www.qtdrugs.org updated lists. Pharmacoepidemiol Drug Saf 2009; 18: 423-24. QT Drug List by Risk Groups [Internet]. Tucson, AZ: Arizona CERT (Center for Education and Research on Therapeutics) [cited 2011 Oct 4]. Available from: http://www.qtdrugs.org/ Summary of Product Characteristics Avelox® 400 mg tablets [Internet]. Newbury, UK: Bayer Pharma [2010, cited 2010 Sept 15]. Available from: http://www.medicines.org.uk/EMC/medicine/ 11841/SPC/Avelox+400+mg+film-coated+tablets Summary of Product Characteristics Avelox® 400 mg/250 ml solution for infusion [Internet]. Newbury, UK: Bayer Pharma [2010, cited 2010 Sept 15]. Available from: http://www.medici nes.org.uk/EMC/medicine/22827/SPC/Avelox+400+mg+250+ml+s olution+for+infusion/ Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from